Overview

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

Status:
Completed

Trial end date:
2017-02-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine a dose of LY2784544 that may be safely administered to participants with myeloproliferative neoplasms.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company